* Ranbaxy faces delays, high costs due to in-house problems
MUMBAI, March 11 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd is in talks with at least two companies on sourcing ingredients for a generic version of AstraZeneca Plc's heartburn pill Nexium
Industries and Ranbaxy Laboratories have recalled batches ..... medication, while Ranbaxy pulled two batches ..... in India and of Ranbaxy ( OTC:RBXLY ..... FDA strictures. Ranbaxy is owned by Japan's Daiichi Sankyo ( OTCPK:DSKYF
MUMBAI, March 8 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd , reeling under a flurry of regulatory rebukes due to manufacturing quality concerns, has recalled more than 64,000 bottles of the...
March 7 (Reuters) - Indian drug maker Ranbaxy Laboratories Ltd has recalled more than 64,000 bottles of the generic versions of its cholesterol-lowering drug in the United States due to reports of a...
AZN ) says Nexium is safe despite an FDA-imposed ban on US shipments on a key ingredient's manufacturer. Ranbaxy Laboratories was slapped with the ban in January because it was allegedly retesting QC-failed products in order to get acceptable
Revenues were driven by recognition of a $5.0 million milestone payment from U.S. Absorica commercialization partner, Ranbaxy , on achieving $150 million in net cumulative sales since the commercial launch of the product in late 2012. We included
* Sources say suspension to affect supplies to Europe, India
* Teva, Ranbaxy to pay $150,000 each to settle with New York State